<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04582981</url>
  </required_header>
  <id_info>
    <org_study_id>FDZL-FRaF</org_study_id>
    <nct_id>NCT04582981</nct_id>
  </id_info>
  <brief_title>Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer</brief_title>
  <official_title>A Randomized, Controlled Phase II Clinical Trial of Fruquintinib Combined With Raltitrexed Versus Fruquintinib Monotherapy in Patients With Advanced Colorectal Cancer Who Had Failed Second-line or Above Standard Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanxi Province Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, controlled phase II clinical trial of Fruquintinib combined with Raltitrexed&#xD;
      versus Fruquintinib monotherapy in patients with advanced colorectal cancer who had failed&#xD;
      second-line or above standard chemotherapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study plans to evaluate the clinical benefits of fruquintinib combined with raltitrexed&#xD;
      compared with fruquintinib single drug treatment in patients with advanced colorectal cancer&#xD;
      who have failed second-line or above treatment, in order to explore the rationality of this&#xD;
      strategy with chemotherapy + targeted combination therapy and obtain the relevant survival&#xD;
      and safety data. A total of 136 patients were planned to be enrolled in this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study is an open-label, randomized, controlled, multi-centered phase II clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival (PFS)</measure>
    <time_frame>assessed up to 24 months</time_frame>
    <description>the time from randomization to tumor progression or death from any cause,whichever came first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>assessed up to 36 months</time_frame>
    <description>the time from randomization to death from any cause,whichever came first,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rate (ORR)</measure>
    <time_frame>through study completion, an average of 2 year</time_frame>
    <description>The proportion of patients whose tumors shrink to a certain extent and remain constant for a certain period of time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease control rate (DCR)</measure>
    <time_frame>through study completion, an average of 2 year</time_frame>
    <description>Percentage of cases with response to treatment (PR+CR) and disease stability (SD) that can be evaluated</description>
  </secondary_outcome>
  <other_outcome>
    <measure>quality of life score (QOL)</measure>
    <time_frame>through study completion, an average of 2 year</time_frame>
    <description>EORTC QOL-C30, version 3.0,</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Advanced Colorectal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination treatment of Fruquintinib and Raltitrexed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy of Fruquintinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fruquintinib and raltitrexed</intervention_name>
    <description>Fruquintinib 5mg qd plus raltitrexed 2mg/m2, q2w</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>F and R</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fruquintinib</intervention_name>
    <description>Fruquintinib 5mg qd monotherapy</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>F</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. no less than 18 years old&#xD;
&#xD;
          2. confirmed by histopathological examination, recurrent/metastatic colorectal&#xD;
             adenocarcinoma&#xD;
&#xD;
          3. had received at least two lines standard chemotherapy and failed. These standard&#xD;
             regimens must include fluorouracil, oxaliplatin, and irinotecan. Treatment failure was&#xD;
             defined as disease progression within 3 months after the last treatment or intolerance&#xD;
             of toxicity or side effects during treatment ; Note: A. each line of treatment shall&#xD;
             include more than one cycle of chemotherapeutic agents; B. adjuvant/neoadjuvant&#xD;
             therapy is allowed in the former treatment. If recurrence or metastasis occurs during&#xD;
             adjuvant/neoadjuvant therapy or within 6 months after completion, adjuvant/neoadjuvant&#xD;
             therapy is considered a failure of first-line chemotherapy for the advanced disease;&#xD;
             C. Prior antitumor therapy regimens using chemotherapy combined with cetuximab or&#xD;
             bevacizumab were permitted.&#xD;
&#xD;
          4. with one or more measurable lesions, according to RECIST criteria, version 1.1;&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance score(PS) from 0 to 2;&#xD;
&#xD;
          6. Life expectancy no less than 12 weeks;&#xD;
&#xD;
          7. Acceptable hematologic, hepatic, and renal function within 7 days from screening： the&#xD;
             blood neutrophil count≥1.5x109 /L; hemoglobin ≥ 9.0 g/dl，the blood platelet count≥80&#xD;
             x109 /L, total bilirubin &lt; 1.5 x upper normal limit（UNL), alanine&#xD;
             aminotransferase（ALT） and aspartate transaminase（AST）&lt; 2.5 x UNL(&lt; 5 x UNL for&#xD;
             patients with live metastasis), serum creatinine≤1 x UNL，endogenous creatinine&#xD;
             clearance rate &gt;50ml/min&#xD;
&#xD;
          8. Women of reproductive age need to take effective contraceptive measures.&#xD;
&#xD;
          9. Participate in this study voluntarily and sign informed consent. Understand the&#xD;
             purpose of this study and the necessary procedures. Good compliance to cooperate with&#xD;
             the follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. urine protein 2 + or above, or 24 hours urinary protein quantitative acuity 1.0 g / 24&#xD;
             h&#xD;
&#xD;
          2. Abnormal coagulation function or those receiving thrombolytics or anticoagulants&#xD;
&#xD;
          3. Patients with tendency of gastrointestinal hemorrhage, including active peptic ulcer&#xD;
             with fecal occult blood ++, hematemesis or melena within 3 months&#xD;
&#xD;
          4. Received other systemic anti-tumor therapy, including cell signal transduction&#xD;
             inhibitors, drug therapy, immune therapy within 3 weeks&#xD;
&#xD;
          5. With uncontrolled high blood pressure (systolic blood pressure &gt; 140 MMHG, diastolic&#xD;
             blood pressure &gt; 90 MMHG)&#xD;
&#xD;
          6. Radiotherapy therapy for target lesions&#xD;
&#xD;
          7. symptomatic cerebral or meningeal metastasis;&#xD;
&#xD;
          8. Uncontrolled pleural or peritoneal effusion&#xD;
&#xD;
          9. Undergoing dialysis&#xD;
&#xD;
         10. Severe or uncontrolled infection&#xD;
&#xD;
         11. With multiple factors that affecting oral administration&#xD;
&#xD;
         12. Former exposed to any VEGFR tyrosine kinase inhibitors (e.g regorafenib, apatinib,&#xD;
             anlotinib etc.) for treatment&#xD;
&#xD;
         13. Raltitrexed treatment for more than one cycle in former line therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weijian Guo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chenchen Wang</last_name>
    <phone>+862164433755</phone>
    <email>wccnancy2003@aliyun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Jian Guo, PHD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Li J, Qin S, Xu RH, Shen L, Xu J, Bai Y, Yang L, Deng Y, Chen ZD, Zhong H, Pan H, Guo W, Shu Y, Yuan Y, Zhou J, Xu N, Liu T, Ma D, Wu C, Cheng Y, Chen D, Li W, Sun S, Yu Z, Cao P, Chen H, Wang J, Wang S, Wang H, Fan S, Hua Y, Su W. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. JAMA. 2018 Jun 26;319(24):2486-2496. doi: 10.1001/jama.2018.7855.</citation>
    <PMID>29946728</PMID>
  </results_reference>
  <results_reference>
    <citation>Pfeiffer P, Yilmaz M, Möller S, Zitnjak D, Krogh M, Petersen LN, Poulsen LØ, Winther SB, Thomsen KG, Qvortrup C. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol. 2020 Mar;21(3):412-420. doi: 10.1016/S1470-2045(19)30827-7. Epub 2020 Jan 27.</citation>
    <PMID>31999946</PMID>
  </results_reference>
  <results_reference>
    <citation>Cunningham D, Zalcberg JR, Rath U, Oliver I, van Cutsem E, Svensson C, Seitz JF, Harper P, Kerr D, Perez-Manga G. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. &quot;Tomudex&quot; Colorectal Cancer Study Group. Ann Oncol. 1996 Nov;7(9):961-5. Erratum in: Ann Oncol 1997 Apr;8(4):407.</citation>
    <PMID>9006748</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 3, 2020</study_first_submitted>
  <study_first_submitted_qc>October 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2020</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Weijian Guo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>advanced colorectal cancer</keyword>
  <keyword>fruquintinib</keyword>
  <keyword>raltitrexed</keyword>
  <keyword>target therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltitrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

